CD274 and non-small cell lung carcinoma: In detail, ICI is currently approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) as single-agent for NSCLC with high (≥50%) expression of programmed death ligand 1 (PD-L1), and in combination with platinum-based chemotherapy regardless of PD-L1 expression (<50%) (1, 2).